利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

193 条记录 (耗时 0.021 秒)

    THIOARYL DERIVATIVES AS GPR120 AGONISTS
    42.
    发明公开
    THIOARYL DERIVATIVES AS GPR120 AGONISTS 审中-公开
    作为GPR120激动剂的噻吩衍生物

    公开(公告)号：EP2914580A4

    公开(公告)日：2016-06-01

    申请号：EP13852301

    申请日：2013-11-05

    申请人： LG LIFE SCIENCES LTD

    发明人： KIM YOUNG KWAN ,  KIM MYOUNG YEOL ,  PARK SANG YUN ,  PARK OK KU ,  ARTEMOV VASILY ,  LEE SANG DAE ,  JOO HYUN WOO ,  CHOI EUN SIL

    IPC分类号： C07D213/80 ,  A61K31/44 ,  A61P3/10 ,  C07D213/70 ,  C07D241/18

    CPC分类号： C07D213/70 ,  A61K31/44 ,  C07D213/80 ,  C07D241/18

    摘要： The present invention relates to thioaryl derivatives of Formula 1 as defined in the specification, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The thioaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in macrophages, pancreas cells, etc. due to anti-inflammatory action, and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, inflammation, obesity, non-alcoholic fatty liver, steatohepatitis or osteoporosis.

    摘要翻译： 本发明涉及说明书中定义的式1的硫代芳基衍生物，其制备方法，包含其的药物组合物及其应用。 根据本发明的式1的硫代芳基衍生物促进胃肠道中的GLP-1形成，并且由于抗炎作用而改善巨噬细胞，胰腺细胞等中的胰岛素抵抗，因此可以有效地用于预防或治疗糖尿病 糖尿病并发症，炎症，肥胖，非酒精性脂肪肝，脂肪性肝炎或骨质疏松症。

    BIARYL DERIVATIVES AS GPR120 AGONISTS
    43.
    发明公开
    BIARYL DERIVATIVES AS GPR120 AGONISTS 审中-公开
    作为GPR120激动剂的双芳基衍生物

    公开(公告)号：EP3013796A1

    公开(公告)日：2016-05-04

    申请号：EP14818620.8

    申请日：2014-06-26

    申请人： LG Life Sciences Ltd.

    发明人： KIM, Young Kwan ,  PARK, Sang Yun ,  JOO, Hyun Woo ,  CHOI, Eun Sil

    IPC分类号： C07D213/30 ,  A61K31/4412 ,  A61P3/00 ,  A61P29/00

    摘要： The present invention relates to biaryl derivatives of Formula 1, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The biaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in the liver or in muscle due to anti-inflammatory action in macrophages, lipocytes, etc., and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, obesity, non-alcoholic fatty liver, steatohepatitis, osteoporosis or inflammation.

    摘要翻译： 本发明涉及式1的联芳衍生物，其制备方法，包含其的药物组合物及其用途。 根据本发明的式1的联芳衍生物促进胃肠道中的GLP-1形成并由于巨噬细胞，脂细胞等中的抗炎作用而改善肝脏或肌肉中的胰岛素抵抗，并且因此可以有效地使用 用于预防或治疗糖尿病，糖尿病并发症，肥胖症，非酒精性脂肪肝，脂肪性肝炎，骨质疏松症或炎症。

    STABLE LIQUID FORMULATION OF ETANERCEPT
    50.
    发明公开
    STABLE LIQUID FORMULATION OF ETANERCEPT 有权
    依那西普的稳定的液体配方

    公开(公告)号：EP2714009A1

    公开(公告)日：2014-04-09

    申请号：EP12793393.5

    申请日：2012-06-01

    申请人： LG Life Sciences Ltd.

    发明人： CHOI, Suk Young ,  KO, Youn Kyung ,  SO, Jin Eon

    IPC分类号： A61K9/08 ,  A61K31/195 ,  A61K31/4172 ,  A61K31/198

    CPC分类号： A61K39/39591 ,  A61K9/0019 ,  A61K9/08 ,  A61K38/1793 ,  A61K47/183 ,  A61K47/20 ,  C07K2319/30

    摘要： The present invention relates to a stable liquid formulation of etanercept (recombinant p75 sTNFR:Fc fusion protein), and more particularly, to a liquid formulation comprising one or more stabilizers selected from the group consisting of methionine, lysine, histidine, and pharmaceutically acceptable salts thereof in an amount sufficient to reduce by-product formation of etanercept during storage. The liquid formulation according to the present invention effectively reduces production of etanercept by-products and to stably maintain its pharmaceutical efficacies for long-term storage. Therefore, the reconstitution procedure is not required before administration, and the sterile formulation can be administered to patients to ensure patient safety. Thus, it can be applied to the fields in need of etanercept treatment.